• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利福昔明对引起旅行者腹泻的肠道病原体的体外抗菌活性。

In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea.

作者信息

Ruiz Joaquim, Mensa Laura, O'Callaghan Cristina, Pons Maria J, González Ana, Vila Jordi, Gascón Joaquim

机构信息

Hospital Clinic, Centro de Salud Internacional (CRESIB); IDIBAPS, Universitat de Barcelona, 08036-Barcelona, Spain.

出版信息

Diagn Microbiol Infect Dis. 2007 Dec;59(4):473-5. doi: 10.1016/j.diagmicrobio.2007.07.003. Epub 2007 Sep 21.

DOI:10.1016/j.diagmicrobio.2007.07.003
PMID:17889485
Abstract

The in vitro activity of rifaximin against 84 diarrheagenic Escherichia coli and 11 Shigella sonnei causing traveler's diarrhea was evaluated. The MIC of rifaximin ranged between <0.007 and 32 mg/L; other agents tested had an MIC of >256 mg/L in most cases. The results showed the potential use of rifaximin to treat these infections.

摘要

评估了利福昔明对84株致泻性大肠杆菌和11株引起旅行者腹泻的宋内志贺菌的体外活性。利福昔明的最低抑菌浓度（MIC）范围在<0.007至32mg/L之间；在大多数情况下，测试的其他药物的MIC>256mg/L。结果表明利福昔明在治疗这些感染方面具有潜在用途。

相似文献

1
In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea.利福昔明对引起旅行者腹泻的肠道病原体的体外抗菌活性。
Diagn Microbiol Infect Dis. 2007 Dec;59(4):473-5. doi: 10.1016/j.diagmicrobio.2007.07.003. Epub 2007 Sep 21.
2
In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea.利福昔明对导致旅行者腹泻的肠道病原体的体外活性。
Antimicrob Agents Chemother. 2001 Feb;45(2):643--4. doi: 10.1128/AAC.45.2.643-644.2001.
3
In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.检测 rifamycin SV 对旅行者腹泻和艰难梭菌相关病原体的体外活性和单步突变分析。
Antimicrob Agents Chemother. 2011 Mar;55(3):992-6. doi: 10.1128/AAC.00688-10. Epub 2010 Dec 13.
4
In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions.四个地理区域中引起旅行者腹泻的细菌性肠道病原体的体外抗菌药敏试验。
Antimicrob Agents Chemother. 2001 Jan;45(1):212-6. doi: 10.1128/AAC.45.1.212-216.2001.
5
In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008.2006 年至 2008 年期间，从前往墨西哥、危地马拉和印度的国际旅行者中分离出的细菌肠病原体的体外抗微生物敏感性。
Antimicrob Agents Chemother. 2011 Feb;55(2):874-8. doi: 10.1128/AAC.00739-10. Epub 2010 Nov 29.
6
Rifaximin--a novel antimicrobial for enteric infections.利福昔明——一种用于肠道感染的新型抗菌药物。
J Infect. 2005 Feb;50(2):97-106. doi: 10.1016/j.jinf.2004.05.019.
7
Rifaximin--the promising anti-microbial for enteric infections.利福昔明——一种用于肠道感染的颇具前景的抗菌药物。
J Infect. 2005 Oct;51(3):262. doi: 10.1016/j.jinf.2005.07.018. Epub 2005 Aug 26.
8
Bile acids improve the antimicrobial effect of rifaximin.胆汁酸可增强利福昔明的抗菌作用。
Antimicrob Agents Chemother. 2010 Sep;54(9):3618-24. doi: 10.1128/AAC.00161-10. Epub 2010 Jun 14.
9
Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.利福昔明：一种用于胃肠道疾病的新型非吸收性利福霉素。
Clin Infect Dis. 2006 Feb 15;42(4):541-7. doi: 10.1086/499950. Epub 2006 Jan 17.
10
In vitro activity and fecal concentration of rifaximin after oral administration.口服后利福昔明的体外活性及粪便浓度
Antimicrob Agents Chemother. 2000 Aug;44(8):2205-6. doi: 10.1128/AAC.44.8.2205-2206.2000.

引用本文的文献

1
A PK/PD model for the evaluation of clinical rifaximin dosage for the treatment of dairy cow mastitis induced by Escherichia coli.用于评估利福昔明治疗大肠杆菌引起的奶牛乳腺炎的临床剂量的 PK/PD 模型。
BMC Vet Res. 2023 Jan 21;19(1):19. doi: 10.1186/s12917-022-03564-2.
2
Antibiotic susceptibility among non-clinical as a marker of antibiotic pressure in Peru (2009-2019): one health approach.秘鲁非临床环境中的抗生素敏感性作为抗生素压力的指标（2009 - 2019年）：一体化健康方法
Heliyon. 2022 Sep 9;8(9):e10573. doi: 10.1016/j.heliyon.2022.e10573. eCollection 2022 Sep.
3
Emergence of Resistance to Quinolones and β-Lactam Antibiotics in Enteroaggregative and Enterotoxigenic Causing Traveler's Diarrhea.
肠聚集性和肠毒性导致旅行者腹泻的耐喹诺酮类和β-内酰胺类抗生素的出现。
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01745-18. Print 2019 Feb.
4
Summary of the Committee to Advise on Tropical Medicine and Travel (CATMAT) Statement on Travellers' Diarrhea.热带医学与旅行咨询委员会（CATMAT）关于旅行者腹泻声明的摘要。
Can Commun Dis Rep. 2015 Nov 5;41(11):272-284. doi: 10.14745/ccdr.v41i11a03.
5
Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.旅行者腹泻防治指南：一份分级专家小组报告。
J Travel Med. 2017 Apr 1;24(suppl_1):S57-S74. doi: 10.1093/jtm/tax026.
6
Pathogen-induced secretory diarrhea and its prevention.病原体诱导的分泌性腹泻及其预防。
Eur J Clin Microbiol Infect Dis. 2016 Nov;35(11):1721-1739. doi: 10.1007/s10096-016-2726-5. Epub 2016 Jul 29.
7
Comparative analysis of antimicrobial resistance in enterotoxigenic Escherichia coli isolates from two paediatric cohort studies in Lima, Peru.秘鲁利马两项儿科队列研究中分离出的产肠毒素大肠杆菌的抗菌药物耐药性比较分析。
Trans R Soc Trop Med Hyg. 2015 Aug;109(8):493-502. doi: 10.1093/trstmh/trv054.
8
Rifaximin therapy of irritable bowel syndrome.利福昔明治疗肠易激综合征
Clin Med Insights Gastroenterol. 2012 Jun 25;5:31-41. doi: 10.4137/CGast.S7382. eCollection 2012.
9
Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain.抗生素对产志贺毒素 2 型大肠杆菌 O104:H4 菌株噬菌体诱导和产毒的影响。
Antimicrob Agents Chemother. 2012 Jun;56(6):3277-82. doi: 10.1128/AAC.06315-11. Epub 2012 Mar 5.
10
Rifaximin for the treatment of acute infectious diarrhea.利福昔明治疗急性感染性腹泻。
Therap Adv Gastroenterol. 2011 Jul;4(4):227-35. doi: 10.1177/1756283X11398734.